期刊文献+

肝、肾移植术后受者环孢素A血药浓度监测的评估 被引量:4

The evaluation of monitoring concentration of whole blood cyclosporine A(CsA) in liver or kidney transplant recipients
下载PDF
导出
摘要 目的探讨肝、肾移植受者环孢素A(CsA)理想的血药浓度监测指标。方法采用荧光偏振免疫法,对65例肝移植受者及136例肾移植受者进行CsA谷浓度(C0)及服药后2 h血药浓度(C2)监测,并对数据进行归纳和分析。结果肝移植受者C2/C0均值为3.56,肾移植受者C2/C0均值为4.8,肝、肾移植受者C2/C0均值有极显著差异(P<0.001);肝移植受者男性CsA血药浓度较女性低。结论C0+C2和C2/C0作为CsA血药浓度监测指标,能更全面地反映CsA体内药物暴露情况和监测CsA肝、肾毒性。 :Purpose To discuss an ideal index of monitoring whole blood concentration of cyclosporine A (CsA) in the patients after a liver or kidney transplantation. Methods The trough concentration (C0) and the peak concentration( C2) of CsA were determined by Fluorescence polarization immunoassay (FPIA) method in 42 cases of liver transplantation and 136 cases of kidney transplantation. Results The mean value of ratio of Co and C2 (C0/C2) in liver transplant recipients and kidney transplant recipients is 3.6 and 4.8 respectively. The mean value of C0/C2 in liver or kidney transplant recipients with different gender was different obviously. Conclusion The value of C0 + C2 and C0/C2 can be an ideal and safe index to reflect the metabolism process of CsA in liver or kidney transplant recipients, especially C0/C2.
出处 《中国生化药物杂志》 CAS CSCD 2008年第2期110-112,共3页 Chinese Journal of Biochemical Pharmaceutics
关键词 肝移植 肾移植 环孢素A 血药浓度 荧光偏振免疫法 liver transplantation kidcncy transplantation cyclosporinc A blood drug concentration fluorescence polarization immunoassay
  • 相关文献

参考文献10

二级参考文献30

  • 1朱有华,顾超宁.肾移植后应用荧光偏振免疫法监测全血环孢素A浓度的经验[J].中华器官移植杂志,1993,14(3):109-111. 被引量:14
  • 2[1]Lindholm A. Therapeutic monitoring of cyclosporine an updata[J]. Eur J Clin Pharmacol,1991,14:114.
  • 3Borel JF. The cyclosporines[J]. Transplant Proc, 1989,21 : 810.
  • 4Dumont R J, Ensom MH. Methods for clinical momitoring of cyclosporine in transplant patients[ J ]. Clin Pharmacokinet, 2000,38(5) :427.
  • 5Jensen SA, Dalhoff KP. Therapeutic monitoring by blood concentrations with the focus on cyclosporine A[ J ] . Ugeskr Laeger,2001,163(14) :2009.
  • 6Levy G. C-2 rronitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation[ J ]. BIO Drugs,2001,15(5) :279.
  • 7Levy G, Burra P, CavaUari A, et al. Improved clinical outcomes for liver transpant recipients using cyclosporine monitoring based on 2-hr post-dose evels(C-2)[ J ]. Transplantation, 2002,73(6) : 953.
  • 8Cantarovieh M, Elstein E, Varennes B, et al. Clinical benefit of Neoral dose monitoring with eyelosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients[J].Transplantation, 1999,68(2) : 1839.
  • 9Kahan BD, Keown P, Levy GA, et a1. Therapeutic drug monitoring of immnnosuppressant drugs in clinical practice. Clin Ther, 2002,24: 330-350.
  • 10Keown P, Landsberg D, Halloran P, et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation,199

共引文献49

同被引文献90

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部